[Chinese guidelines on clinical application of autoimmune bullous diseases related autoantibodies (2026)].

Autoimmune bullous diseases (AIBDs) are a group of organ-specific autoimmune disorders caused by autoantibodies directed against skin adhesion structures. Their diagnosis and treatment heavily rely on accurate autoantibody testing. To address current challenges in China, such as the diversity of AIBDs testing methods and lack of standardization, the National Clinical Research Center for Rheumatic and Autoimmune Diseases (Peking Union Medical College Hospital) initiated the development of this guideline. In collaboration with the Key Laboratory of Rheumatology and Immunology of the Ministry of Education, National Professional Healthcare Quality Control Center for Immunology (Including Allergy), Rheumatology and Immunology Physician Committee of Chinese Medical Doctor Association, and Rheumatology Society of Chinese Medical Association, a multidisciplinary expert working group was established. Based on the latest international evidence and clinical practice in China, the group formulated this guideline by strictly adhering to evidence-based guideline development methods and procedures. This guideline focuses on eight key issues related to laboratory testing for AIBDs in China. It covers the application of autoantibodies in the diagnosis, subtyping, disease assessment, treatment guidance, identification of applicable populations, determination of testing timing, result interpretation, and quality management of AIBDs. The aim is to enhance the laboratory's capabilities in autoantibody testing and result interpretation, and offer important references for advancing precision diagnosis and treatment of the disease.